Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

• Status: Terminated
• Trial end date: 2021-02-23
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: Portland VA Medical Center
• Treatments: Amantadine; Buspirone; Levodopa

Criteria

Inclusion Criteria:

• Parkinson's disease diagnosis

• Currently taking a levodopa containing medication for Parkinson's disease

• Mild to Severe dyskinesia

• Currently taking between 200-500 mg of amantadine daily for treatment of levodopa-induced dyskinesia with insufficient suppression levodopa-induced dyskinesia.

• Stable medication regimen for at least 4 weeks prior to study.

Exclusion Criteria:

• Currently receiving any other treatment for levodopa-induced dyskinesia, including but not exclusive to deep brain stimulation.

• Not able to follow verbal commands

• Not able to stand unsupported for at least 60 seconds

• Not able to answer a patient questionnaire about their symptoms of Parkinson's disease and dyskinesia.

• Have proprioceptive deficits.

• Have a history of hepatic impairment

• Currently have severe renal impairment

• Currently have any other medical or psychiatric diagnosis that would preclude their ability to safely participate in the study.

• Significant cognitive impairment

• Pregnancy

• Breast-Feeding

• Unable to swallow study drug (capsule)